Atorvastatin antagonizes the visfatin-induced expression of inflammatory mediators via the upregulation of NF-κB activation in HCAECs

Shi,Kai‑Lei; Qian,Ju‑Ying; Qi,Lin; Mao,Ding‑Biao; Chen,Yang; Zhu,Yi; Guo,Xin‑Gui

doi:10.3892/ol.2016.4796

Atorvastatin antagonizes the visfatin-induced expression of inflammatory mediators via the upregulation of NF-κB activation in HCAECs

Authors:
- Kai‑Lei Shi
- Ju‑Ying Qian
- Lin Qi
- Ding‑Biao Mao
- Yang Chen
- Yi Zhu
- Xin‑Gui Guo
View Affiliations

Affiliations: Department of Cardiology, Huadong Hospital Affiliated to Fudan University, Shanghai 200040, P.R. China, Department of Cardiology, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China, Department of Radiology, Huadong Hospital Affiliated to Fudan Universtiy, Shanghai 200040, P.R. China
Published online on: June 28, 2016 https://doi.org/10.3892/ol.2016.4796
Pages: 1438-1444
Copyright: © Shi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study investigated whether atorvastatin antagonizes the visfatin-induced expression of inflammatory mediators in human coronary artery endothelial cells (HCAECs). Several analysis methods, such as reverse transcription-quantitative polymerase chain reaction, western blot analysis and H2DCFDA incubation, were used in the present study. The data showed that atorvastatin decreased the visfatin-induced expression of interleukin (IL)‑6 and IL‑8 in HCAECs. In addition, atorvastatin inhibited the visfatin‑induced expression of intercellular adhesion molecule‑1 and vascular cell adhesion molecule‑1 in HCAECs. In addition, the present study found that atorvastatin inhibited the visfatin‑activated nuclear factor‑κB (NF‑κB) signal pathway by preventing extracellular signal‑regulated kinase phosphorylation in HCAECs. Atorvastatin significantly inhibited visfatin‑induced NF‑κB activity via the upregulation of reactive oxygen species production. Atorvastatin, a visfatin antagonist (FK866) and an NF‑κB inhibitor (BAY11‑7082) decreased the visfatin-induced expression of inflammatory mediators via the upregulation of NF‑κB activation in HCAECs. These results suggest that atorvastatin may inhibit the visfatin-induced upregulation of inflammatory mediators through blocking the NF‑κB signal pathway. The findings of the present study provide a potential use for atorvastatin and visfatin in the pathogenesis of HCAEC dysfunction. This knowledge may contribute to the development of novel therapies for atherosclerosis.

View Figures

View References

1	Rashid MN, Fuentes F, Touchon RC and Wehner PS: Obesity and the risk for cardiovascular disease. Prev Cardiol. 6:42–47. 2003. View Article : Google Scholar : PubMed/NCBI
2	Ajuwon KM and Spurlock ME: Adiponectin inhibits LPS-induced NF-kappaB activation and IL-6 production and increases PPARgamma2 expression in adipocytes. Am J Physiol Regul Integr Comp Physiol. 288:R1220–R1225. 2005. View Article : Google Scholar : PubMed/NCBI
3	Anfossi G, Russo I, Doronzo G, Pomero A and Trovati M: Adipocytokines in atherothrombosis: Focus on platelets and vascular smooth muscle cells. Mediators Inflamm. 2010:1743412010. View Article : Google Scholar : PubMed/NCBI
4	Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Imai Y, Manabe I, Utsunomiya K and Nagai R: Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: A new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun. 314:415–419. 2004. View Article : Google Scholar : PubMed/NCBI
5	Lau DC, Dhillon B, Yan H, Szmitko PE and Verma S: Adipokines: Molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol. 288:H2031–H2041. 2005. View Article : Google Scholar : PubMed/NCBI
6	Berg AH and Scherer PE: Adipose tissue, inflammation and cardiovascular disease. Circ Res. 96:939–949. 2005. View Article : Google Scholar : PubMed/NCBI
7	Guerre-Millo M: Adipose tissue and adipokines: For better or worse. Diabetes Metab. 30:13–19. 2004. View Article : Google Scholar : PubMed/NCBI
8	Sethi JK and Vidal-Puig A: Visfatin: The missing link between intra-abdominal obesity and diabetes? Trends Mol Med. 11:344–347. 2005. View Article : Google Scholar : PubMed/NCBI
9	Wu ZH and Zhao SP: Adipocyte: A potential target for the treatment of atherosclerosis. Med Hypotheses. 67:82–86. 2006. View Article : Google Scholar : PubMed/NCBI
10	Blankenberg S, Barbaux S and Tiret L: Adhesion molecules and atherosclerosis. Atherosclerosis. 170:191–203. 2003. View Article : Google Scholar : PubMed/NCBI
11	Libby P, Ridker PM and Maseri A: Inflammation and atherosclerosis. Circulation. 105:1135–1143. 2002. View Article : Google Scholar : PubMed/NCBI
12	Kougias P, Chai H, Lin PH, Yao Q, Lumsden AB and Chen C: Effects of adipocyte-derived cytokines on endothelial functions: Implication of vascular disease. J Surg Res. 126:121–129. 2005. View Article : Google Scholar : PubMed/NCBI
13	Kralisch S, Sommer G, Stangl V, Köhler U, Kratzsch J, Stepan H, Faber R, Schubert A, Lössner U, Vietzke A, et al: Secretory products from human adipocytes impair endothelial function via nuclear factor kappaB. Atherosclerosis. 196:523–531. 2008. View Article : Google Scholar : PubMed/NCBI
14	Cooke JP and Oka RK: Does leptin cause vascular disease? Circulation. 106:1904–1905. 2002. View Article : Google Scholar : PubMed/NCBI
15	Kougias P, Chai H, Lin PH, Lumsden AB, Yao Q and Chen C: Adipocyte-derived cytokine resistin causes endothelial dysfunction of porcine coronary arteries. J Vasc Surg. 41:691–698. 2005. View Article : Google Scholar : PubMed/NCBI
16	Samal B, Sun Y, Stearns G, Xie C, Suggs S and McNiece I: Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol. 14:1431–1437. 1994. View Article : Google Scholar : PubMed/NCBI
17	Sommer G, Garten A, Petzold S, Beck-Sickinger AG, Blüher M, Stumvoll M and Fasshauer M: Visfatin/PBEF/Nampt: Structure, regulation and potential function of a novel adipokine. Clin Sci (Lond). 115:13–23. 2008. View Article : Google Scholar : PubMed/NCBI
18	Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H and Tilg H: Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol. 178:1748–1758. 2007. View Article : Google Scholar : PubMed/NCBI
19	Lee WJ, Wu CS, Lin H, Lee IT, Wu CM, Tseng JJ, Chou MM and Sheu WH: Visfatin-induced expression of inflammatory mediators in human endothelial cells through the NF-kappaB pathway. Int J Obes (Lond). 33:465–472. 2009. View Article : Google Scholar : PubMed/NCBI
20	Guzik TJ, Mangalat D and Korbut R: Adipocytokines-novel link between inflammation and vascular function? J Physiol Pharmacol. 57:505–528. 2006.PubMed/NCBI
21	Kim SR, Bae YH, Bae SK, Choi KS, Yoon KH, Koo TH, Jang HO, Yun I, Kim KW, Kwon YG, et al: Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochim Biophys Acta. 1783:886–895. 2008. View Article : Google Scholar : PubMed/NCBI
22	Buldak RJ, Gowarzewski M, Buldak L, Skonieczna M, Kukla M, Polaniak R and Zwirska-Korczala K: Viability and oxidative response of human colorectal HCT-116 cancer cells treated with visfatin/eNampt in vitro. J Physiol Pharmacol. 66:557–566. 2016.
23	Carmeliet P: Angiogenesis in health and disease. Nat Med. 9:653–660. 2003. View Article : Google Scholar : PubMed/NCBI
24	Kim SR, Bae SK, Choi KS, Park SY, Jun HO, Lee JY, Jang HO, Yun I, Yoon KH, Kim YJ, et al: Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. Biochem Biophys Res Commun. 357:150–156. 2007. View Article : Google Scholar : PubMed/NCBI
25	Dahl TB, Yndestad A, Skjelland M, Øie E, Dahl A, Michelsen A, Damås JK, Tunheim SH, Ueland T, Smith C, et al: Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: Possible role in inflammation and plaque destabilization. Circulation. 115:972–980. 2007. View Article : Google Scholar : PubMed/NCBI
26	Kotsopoulos J, Zhang S, Akbari M, Salmena L, Llacuachaqui M, Zeligs M, Sun P and Narod SA: BRCA1 mRNA levels following a 4–6-week intervention with oral 3,3′-diindolylmethane. Br J Cancer. 111:1269–1274. 2014. View Article : Google Scholar : PubMed/NCBI
27	Simonini A, Moscucci M, Muller DW, Bates ER, Pagani FD, Burdick MD and Strieter RM: IL-8 is an angiogenic factor in human coronary atherectomy tissue. Circulation. 101:1519–1526. 2000. View Article : Google Scholar : PubMed/NCBI
28	Yudkin JS, Kumari M, Humphries SE and Mohamed-Ali V: Inflammation, obesity, stress and coronary heart disease: Is interleukin-6 the link? Atherosclerosis. 148:209–214. 2000. View Article : Google Scholar : PubMed/NCBI
29	Takahashi M, Ikeda U, Masuyama J, Kitagawa S, Kasahara T, Shimpo M, Kano S and Shimada K: Monocyte-endothelial cell interaction induces expression of adhesion molecules on human umbilical cord endothelial cells. Cardiovasc Res. 32:422–429. 1996. View Article : Google Scholar : PubMed/NCBI
30	Han SG, Newsome B and Hennig B: Titanium dioxide nanoparticles increase inflammatory responses in vascular endothelial cells. Toxicology. 306:1–8. 2013. View Article : Google Scholar : PubMed/NCBI
31	Adya R, Tan BK, Chen J and Randeva HS: Nuclear factor-kappaB induction by visfatin in human vascular endothelial cells: Its role in MMP-2/9 production and activation. Diabetes Care. 31:758–760. 2008. View Article : Google Scholar : PubMed/NCBI
32	Adya R, Tan BK, Punn A, Chen J and Randeva HS: Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: Novel insights into visfatin-induced angiogenesis. Cardiovasc Res. 78:356–365. 2008. View Article : Google Scholar : PubMed/NCBI
33	Collins T, Read MA, Neish AS, Whitley MZ, Thanos D and Maniatis T: Transcriptional regulation of endothelial cell adhesion molecules: NF-kappaB and cytokine-inducible enhancers. FASEB J. 9:899–909. 1995.PubMed/NCBI
34	Said RS, El-Demerdash E, Nada AS and Kamal MM: Resveratrol inhibits inflammatory signaling implicated in ionizing radiation-induced premature ovarian failure through antagonistic crosstalk between silencing information regulator 1 (SIRT1) and poly(ADP-ribose) polymerase 1 (PARP-1). Biochem Pharmacol. 103:140–150. 2016. View Article : Google Scholar : PubMed/NCBI
35	Görlach A, Bertram K, Hudecova S and Krizanova O: Calcium and ROS: A mutual interplay. Redox Biol. 6:260–271. 2015. View Article : Google Scholar : PubMed/NCBI
36	Chaudhari N, Talwar P, Parimisetty A, d'Hellencourt Lefebvre C and Ravanan P: A molecular web: endoplasmic reticulum stress, inflammation, and oxidative stress. Front Cell Neurosci. 8:2132014. View Article : Google Scholar : PubMed/NCBI
37	Shirai K: Obesity as the core of the metabolic syndrome and the management of coronary heart disease. Curr Med Res Opin. 20:295–304. 2004. View Article : Google Scholar : PubMed/NCBI
38	Van Gaal LF, Mertens IL and De Block CE: Mechanisms linking obesity with cardiovascular disease. Nature. 444:875–880. 2006. View Article : Google Scholar : PubMed/NCBI
39	Kim YR, Koh HJ, Kim JS, Yun JS, Jang K, Lee JY, Jung JU and Yang CS: Peptide inhibition of p22phox and Rubicon interaction as a therapeutic strategy for septic shock. Biomaterials. 101:47–59. 2016. View Article : Google Scholar : PubMed/NCBI
40	Ruiz-Ojeda FJ, Gomez-Llorente C, Aguilera CM, Gil A and Rupérez AI: Impact of 3-amino-1,2,4-triazole (3-AT)-derived increase in hydrogen peroxide levels on inflammation and metabolism in human differentiated adipocytes. PLoS One. 11:e01525502016. View Article : Google Scholar : PubMed/NCBI
41	Satoh R, Kakugawa K, Yasuda T, Yoshida H, Sibilia M, Katsura Y, Levi B, Abramson J, Koseki Y, Koseki H, et al: PLoS Genet. 12:e10057762016. View Article : Google Scholar : PubMed/NCBI